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Methods:This is an open label Phase I clinical dose escalation study
with the primary goal to assess safety of MultiStem as an adjunct
therapy for adult hematological malignancy patients shortly after al-
logeneic HSCT. Patients were enrolled for stromal cell administra-
tion as a single dose or in multiple weekly doses. Infusional toxicity
andRRTswas assessed for 30 days following the last dose. Secondary
endpoints included incidence of acute GVHD, infection and survival
through day 100. Dose escalation was guided by the Continual Re-
assessment Method (CRM).
Results: Enrollment was completed for the target of 36 patients
from 5 clinical centers for this Phase I clinical trial. 18 patients re-
ceived a single dose MultiStem IV at 1, 5, or 10 million cells per
kg at day 2 and 18 patients received MultiStem IV at 1 or 5 million
cells per kg at days 2, 9 and 16 or days 2, 9, 16 and 30 after allogeneic
HSCT. There was no observed infusional toxicity in either arm.
Two patients in the single dose arm experienced Bearman RRTs
(Grade 3 mucositis; Grade 3 renal and pulmonary failure). These
events were deemed unrelated to study product. In the multi-dose
cohort, one patient experienced liver GVHD, deemed possibly re-
lated to study product. Engraftment occurred in all 36 patients and
the median time to neutrophil engraftment was 15 days (range, 11-
25 days). The 100-day cumulative incidence of Grade II-IV and
III-IV GVHD was 28% and 6%, respectively in the single dose
arm. Preliminary evaluations of the repeat dose arm showed 21%
and 11% Grade II-IV and III-IV GVHD, respectively. The highest
tested single and repeat dose regimens showed the lowest GVHD
frequencies.
Conclusion: Single dose and repeat dose administration of Multi-
Stem is well-tolerated, without observation of infusional toxicity or
graft failure. The observed low incidence of severe acute GVHD
supports the concept that this stromal stem cell therapy product is
safe and can be harnessed as a novel therapeutic option for GVHD
prophylaxis following HSCT.
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TREATMENT OF STEROID RESISTANT GRADE II TO IV ACUTE GVHD BY
INFUSION OF MESENCHYMAL STROMA CELLS EXPANDED WITH HUMAN
PLASMA AND PLATELET LYSATE – A PHASE I/II STUDY
Boome, L.C.J.1, Mansilla Puerta, C.M.2, Lindemans, C.A.3,
Slaper, I.C.M.4, Rozenmuller, H.4, Petersen, E.J.1, Bierings, M.3,
Boelens, J.J.3, Wulffraat, N.H.3, Kuball, J.H.E.1,2 1UMCU, Utrecht,
Netherlands; 2UMCU, Utrecht, Netherlands; 3UMCU, Utrecht,
Netherlands; 4UMCU, Utrecht, Netherlands
Introduction: For numerous hematological diseases allogeneic
HSCT is the only curative therapy. Despite multiple improvements
in the last decade in the field of HSCT, aGVHD remains a life-
threatening complication. In particular, the outcome of patients
with severe steroid-resistant aGVHD is very poor. Therefore, it re-
mains important to search for new therapeutic strategies for the
treatment of aGVHD.
Objective: To study the feasibility, safety and efficacy of MSCs ex-
panded with human plasma and platelet lysate (hPPL), in patients
with steroid-refractory aGVHD.
Method: In an open-label, non-randomized prospective phase I/II
study patients with steroid-refractory aGVHD grade II to IV were
treated with2x106/kgMSC. Response rate, TRM, and AEwere as-
sessed for up to 1 yr after inclusion. Serum and bloodsamples from
were collected.
Results: Between January 2009 and December 2010, 20 patients
were included, 2 drop out, and 18 were available for further analysis:
5 children and 13 adults. Median age was 32.5yr (range 1.3-65.9).
Organs involved in aGVHD were skin (67%), GI-tract (83%) and
liver (28%). Overall grade was II for 22%, III for 72%, and IV for
6% patients. 1 patient received one infusion, all other patients re-
ceived two or more infusions. Median follow-up was 5.5m (range
0.33-12). Complete response was observed in 11 patients 61%,
after a median of 65 days (range 10-184 days). The OS was signifi-
cantly better in responders when compared to non-responders
(p\0.001). Of the 11 patients who reached a CR, 8 patients relapsed
approximately 2 months after reaching CR (median 59 days, range:
1-244). Three children relapsed with clinical signs of an allo-
immune-lung, auto-immune-cytopenia or limited cGVHD and all5 adults relapsed with GVHDof the gut (median 98 days after reach-
ing CR, range: 35-302 days). However, GVHD of the gut was then
again sensitive to steroids. Overall, 7 patients died, 4 due to progres-
sion of aGVHD, 1 patient due to abdominal bleeding and 2 due to
sepsis.
Extensive biomarkeranalysis were performed. We found bio-
markers who are associated with clinical response of patients.
Conclusion: Generation and infusion of MSCs in steroid-resistant
aGVHD grade II- IV is feasible, safe and very effective. In addition,
also patients who initially responded toMSCs but develop later a re-
lapse of aGVHDduring tapering or cessation of immunosuppressive
drugs become again sensitive to the treatment with steroids. Clinical
response can be predicted by biomarkers.
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IN SEARCH FOR MOLECULES INVOLVED IN THE IMMUNOSSUPRESSION
INDUCED BY MESENCHYMAL STROMAL CELLS
Du Rocher, B.1,2, Mencalha, A.1,2, Binato, R.1,2, Dutra, T.1,2,
Bouzas, L.F.1, Abdelhay, E.1,2 1 Instituto Nacional de Cancer, Rio de
Janeiro, Brazil; 2Universidade Federal do Rio de Janeiro, Rio de Janeiro,
Brazil
Background:Mesenchymal stromal cells (MSCs) improve hemato-
poietic recovery, contribute to tissue regeneration and posses immu-
nosuppressive properties. Because of these unique properties their
applicability in the bone marrow transplantation has attracted
much attention, especially as a promising therapy to control graft-
versus-host disease. In this way, a better understanding of how
MSCs induce immunosuppresion can give us the rational needed
for the most appropriate use of these cells.
Objectives:This study aimed to search for soluble factors produced
by MSCs that can potentially be involved in the mechanism of
immunosuppression.
Methods:Mixed leucocyte reactions, were incubated in the absence
or presence of 10% MSCs in a contact independent manner using
a polycarbonate membrane (transwell) between MLRs and MSCs.
After three or seven days, cultures were analysed using flow cytomety
or submited to global gene expression analyses.
Results: We found 672 mRNAs increased and 311 mRNAs de-
creased in at least 2X. 70% of mRNAs increased in MSCs in co-
culture were related to immune response. Of these, it was notorious
the increased in mRNAs associated with antigen presentation via
MHC I and II (8%), chemokine (9%), metabolism / transport of
lipids (9%) and regulatory proteins induced by IFN-y (18 %).
The pathways most likely to be activated inMSCs after co-culture
were IFN-y and IL-17. Among the 672molecules increased inMSCs
we choose COX-2 and the chemokines CCL8 e CXCL8 to evaluate
their functions during the immunosuppression induced by MSCs.
The use of indomethacin, a COX inhibitor, in co-cultures reversed
the inhibitory effect of MSCs. Moreover, when separated from
MLRs by a transwell of 0.5mM, which allows the passage of cells,
we observed a greater suppression of those lymphocytes that mi-
grated to the MSCs’s niche, suggesting that chemokines are impor-
tant in this process.
Conclusions: After co-culture MSCs changed from an inactivated
state, ‘‘steady state’’, to an activated state. This process induced their
immunosuppressive phenotype, which involves COX2 and differents
chemokines. The specific role of CCL8 and CXCL8 is under inves-
tigation.
Financial support:MS, CNPq, and FAPERJ.168
MESENCHYMAL STROMAL CELLS IMPAIR THE DIFFERENTIATION OF
CD14++CD16-CD64+ CLASSICALMONOCYTES INTO CD14++CD16+CD64++
ACTIVATE MONOCYTES
Du Rocher, B.1,2, Mencalha, A.1,2, Gomes, B.E.1,2, Bouzas, L.F.1,
Abdelhay, E.1,2 1 Instituto Nacional de Cancer, Rio de Janeiro, Brazil;
2Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
Background:Mesenchymal stromal cells (MSCs) possess immuno-
modulatory activity both in vitro and in vivo. However, little
information is available about their function during the initiation
of immunological responses through their interactions with
S266 Poster Session Imonocytes. While many studies have shown that MSCs impair the
differentiation of monocytes into dendritic cells and macrophages,
there are few articles showing the interaction between MSCs and
monocytes and none of them have addressed the question of mono-
cyte subsets modulation.
Methods: To better understand the mechanism behind the benefit
ofMSCs infusion for graft-versus-host treatment throughmonocytes
involvement, we performedmixed leucocytes reactions (MLR) in the
presence or absence of MSCs. After three or seven days, cultures
were analyzed by flow cytometry using different approaches.
Results:MSCs induced changes in monocyte phenotype in a MLR.
This alteration was accompanied by an increase in monocyte count-
ing and in CD14 expression. MSCs induced monocyte alterations
even without contact, although the parameters above weremore pro-
nounced with cell-cell contact. Moreover, the presence of MSCs im-
paired MHC I and II, CD11c, CCR5 expression and induced CD14
and CD64 expression on monocytes. These alterations were accom-
panied by a decrease in IL-1b and IL-6 production by these mono-
cytes but no change was observed taking into account the
phagocytosis capacity of these monocytes.
Conclusions: Our results suggest that MSCs impair the dif-
ferentiation of CD14++CD16-CD64+ classical monocytes into
CD14++CD16+CD64++ activate monocytes, having a role even ear-
lier than the differentiation of monocytes into dendritic cells and
macrophages.
Keywords: Immunosuppression, Mesenchymal stromal cells,
Monocyte subsets
Financial support: MS, CNPq, and FAPERJ.
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EFFECTIVE MOBILIZATION OF MESENCHYMAL STEM CELLS IN C57BL/6
MICE UTILIZING SINGLE AGENT PLERIXAFOR (AMD3100) OR IN COMBI-
NATION WITH NEUPOGEN (G-CSF)
Frank, R.R.1, Jagan, S.1, Paganessi, L.A.1, McNulty, M.A.2,
Sumner, D.R.2, Fung, H.C.1, Gregory, S.A.1, Christopherson, K.W.1,2
1Rush University Medical Center, Chicago, IL; 2Rush University Medical
Center, Chicago, IL
Introduction:Mesenchymal stem cells (MSC) are a rare population
of cells that have the ability to form muscle, bone, cartilage, and ad-
ipose. MSC can be obtained from the bone marrow (BM). Strategies
to mobilize MSC into the peripheral blood (PB) where they can be
easily collected would be of therapeutic benefit but there is a lack
of consensus on effective strategies to mobilize MSC.
Methods: During a screen in C57BL/6 mice, subcutaneous (SC)
injections of neupogen (G-CSF) or plerixafor (AMD3100) were
identified as agents that mobilize MSC. Subsequently, neupogen
(G-CSF, 50mg/kg SC twice a day for 4 days) and plerixafor
(AMD3100, 5mg/kg SC, once 1 hr prior) were assessed in individual
mice (N 5 5) as single agents or in combination. PB and BM were
collected and plated for colony formation in 5%CO2 5%O2 for 7
days.MSC colonies were scored as colony formation units-fibroblast
(CFU-F total, large, & small) in parallel with hematopoietic progen-
itors (CFU-GM, BFU-E, and CFU-GEMM). Data is presented as
colonies /mL PB or /femur 6 SEM and analyzed using Mann-
Whitney U test.
Results: Analysis of data showed that, as compared to saline, treat-
ment with G-CSF and to a greater extent AMD3100 resulted in mo-
bilization of total CFU-F (large & small CFU-F) into the PB
(5.562.5, 22.165.3, and 135.8611.5 CFU-F/mL respectively
(p\0.05). Combination G-CSF+AMD3100 mobilized at levels
(110.565.1 CFU-F/mL) not statistically different than single agent
AMD3100 (p\0.05). Analysis of the large CFU-F colonies revealed
that a significant number of large CFU-F were mobilized with
AMD3100 or combination G-CSF+AMD3100 (p\0.05), but not
G-CSF alone. In the BM, the total number of CFU-F, as compared
to saline, was decreased in response to G-CSF or G-CSF +
AMD3100, but not single agent AMD3100 (p\0.05). The response
of hematopoietic progenitor mobilization to the agents tested was as
expected: G-CSF, AMD3100, or G-CSF+AMD3100 mobilize
CFU-GM, BFU-E, and CFU-GEMM into the PB with the greatest
level of mobilization resulting from G-CSF+AMD3100 (p\0.05).
Conclusion: Single agent AMD3100 administered SC is effective at
mobilizing mouse MSC (total CFU-F or large CFU-F) with no
additional enhancement from combination G-CSF+AMD3100.G-CSF treatment, alone or in combination, depletes MSC in the
bonemarrowwhereas treatment with AMD3100 does not. This sug-
gests that use of single agent plerixafor (AMD3100) may be an effec-
tive strategy to mobilize MSC for use in the context of regenerative
medicine.
170
EPAC ACTIVATION REGULATES HUMAN MESENCHYMAL STEM CELLS
MIGRATION AND ADHESION
Yu, J.-L.1, Chung, S.K.2, Chan, G.C.-F.1 1The University of Hong Kong,
Hong Kong Special Administration Region, China; 2The University of
Hong Kong, Hong Kong Special Administration Region, China
Currently, one of the challenges confronted by the clinical appli-
cations of human mesenchymal stem cells (hMSCs) is how to en-
hance the homing and engraftment of hMSCs to the target tissues
with high efficiency. To overcome such barrier, mechanisms respon-
sible for the hMSCs homing and engraftment are one of the key re-
search foci. As of now, the exact mechanism and soluble factors
involved in migration and adhesion of hMSCs have not been com-
pletely unfolded. Exchange protein directly activated by cAMP
(Epac), a novel protein discovered in cAMP signaling pathway, at-
tracts our attention due to its potential role in regulating cells adhe-
sion and migration by triggering the downstream Rap family
signaling cascades.However, the exact biological role of Epac in cells
homing remains elusive and even controversial. Our study aimed to
evaluate the regulatory effects of Epac in the homing process of
hMSCs. We confirmed that hMSCs expressed functional Epac. In
addition, Epac activation stimulated by specific analogue enhanced
the adhesion and migration capacities of hMSCs significantly.
Such homing enhancement effects were associated with correspond-
ing morphological changes induced by Epac. The Epac activation
was further found to be contributed directly to the chemotactic re-
sponses induced by stromal cell derived factor-1 (SDF-1) which is
a known crucial chemokine in regulating hMSCs homing. These
findings suggested Epac is connected to the SDF-1 signaling cas-
cades. In conclusion, our study revealed that Epac plays a role in
hMSCs homing by promoting adhesion, migration and also by en-
hancing chemotactic effect induced by SDF-1. Appropriate manipu-
lation of Epac may enhance the homing and engraftment of hMSCs
and facilitate the future clinical applications of hMSCs.171
ROLE OF NFATC2 IN PROLIFERATION AND DIFFERENTIATION OF HUMAN
CD34+ HEMATOPOIETIC STEM CELLS
Salhotra, A., Yang, S., Paul, T., Lu, H., Huang, X., Wendling, A.,
Farmer, J., Masri, H.E.I., Laughlin, M.J. University of Virginia,
Charlottesville, VA
Background: Cyclosporine-A (CSA) inhibits NFATc2 activation
and is effective in management of graft versus host disease
(GVHD). Little is known of the role of NFATc2 transcription factor
and its inhibition, in affecting differentiation and proliferation of
CD34+ HSC’s (Hematopoietic Stem Cells).
Methods:We used Ficoll density gradient method to obtain Mono-
nuclear Cell (MNC) from human cord blood units (provided by Pa-
blo Rubinstein, MD, New York Blood Center). MNC’s were
enriched for CD34+ HSC’s using magnetic bead separation (Auto
Macs, Miltenyi) which were plated at density of 60,000 cells / ml
in serum free media with IL-3 (5ng/ml), FLT-3L (100 ng/ml),
SCF (50 ng/ml), G-CSF (30 ng/ml) and GM-CSF (5ng/ml). Cells
were cultured under normoxic conditions for 7 days at 37.0C with
5%CO2. HSC proliferation and differentiation was studied in pres-
ence and absence of CSA.
Results:Flow cytometry analysis of HSC’s grown in absence of CSA
showed high CD 34 (84.7%) and low CD33/ HLA-DR (0.57% and
5.71 % respectively) expression on Day 0 of culture. In presence of
CSA at 2mM concentration, we noted a more rapid rise of CD33
(41.0% versus 28.1%) HLA-DR (44.4% versus 29.1%) and CD 71
(12 % Vs 24.4%) markers by day 7. No difference was noted in total
cell count in CSA treated 701,666.66 7637 (mean and SD) and un-
treated 643,333 6 5166 conditions.
